Montanaro UK Smaller Companies Investment Trust PLC
Interim Management Statement - 3 months to 31 December 2009
Investment Objective
MUSCIT's investment objective is capital appreciation (rather than income)
achieved by investing in small quoted companies listed on the London Stock
Exchange or traded on the Alternative Investment Market ("AIM") and to achieve
relative outperformance of its benchmark, the FTSE "SmallCap" (excluding
investment companies) Index ("SmallCap"). No unquoted investments are
permitted.
Investment Policy
The Company looks to achieve its objective and to diversify risk by investing
in a portfolio of UK Smaller Companies. At the time of initial investment, a
potential investee company must be profitable and smaller than the largest
constituent of the HGSC Index, which represents the smallest 10% of the UK
Stock Market by value. At the start of 2010, this was any company below £1.188
billion in size. The Manager looks to focus on the smaller end of this Index.
In order to manage risk the Manager will normally limit any one holding to a
maximum of 5% of the Company's investments. The weightings for every stock are
closely monitored to ensure they reflect the underlying liquidity of the
particular company. The Company's AIM exposure is also closely monitored by the
Board and is limited to 30% of total investments with Board approval required
for exposure to be above 25%.
The Manager is focused on identifying high quality niche companies operating in
growth markets. This typically leads the Manager to invest in companies that
enjoy high barriers to entry, a sustainable competitive advantage and strong
management teams. The portfolio is therefore constructed on a "bottom up" basis
and there are no sectoral constraints placed on the Manager.
The Board, in consultation with the Manager, is responsible for determining the
gearing strategy for the Company. Gearing is used to enhance returns when the
timing is considered appropriate. The Company currently has a credit facility
of £15 million through ING Bank of which £10m is currently drawn down. The
Board has agreed to limit borrowings to 25% of shareholders' funds.
Benchmark
FTSE SmallCap (excluding Investment Companies)
Net Asset Value Performance
3 months 6 months 1 year 3 years 5 years Launch
MUSCIT 3.4% 26.5% 42.6% (18.2%) 38.3% 187.7%
Benchmark (8.2%) 23.1% 52.7% (39.3%) (15.3%) 37.3%
Performance Summary (capital only)
As at 31 As at 30 Movement
December 2009 September 2009
Gross assets £105,963,954 £103,598,061 2.3%
Net asset value 286.09p 277.67p 3.0%
per share
Share price 227.00p 226.00p 0.4%
Discount 20.7% 18.6%
Actual Gearing 10.4% 10.8%
Net Gearing 9.5% 10.1%
Period Review
The third quarter of the Company's financial year to 31 December 2009 saw
positive absolute and relative performance. This was a welcome relief after a
previous challenging six months of underperformance. During this time, there
was a sharp recovery in operationally and financially geared companies that are
not compatible with the Manager's quality investment style.
The FTSE SmallCap Index fell 8% in the fourth quarter of 2009 and
underperformed large stocks for the first time this year. Despite a rather dull
final three months, 2009 was a stellar year for SmallCap. From the period from
9 March to 19 October our benchmark the FTSE SmallCap Index returned 93%,
delivering outperformance of a remarkable 44% against the FTSE 100 Index. After
such a dramatic move, a period of consolidation was to be expected.
Despite this, positive returns could still be obtained from good stock
selection. The portfolio's NAV rose by 3% over the quarter, an outperformance
of 12%. The Company benefited from the shift in the market's style bias away
from recovery stocks in favour of quality growth. This market environment is
one to which the house style is more suited.
The Company's strongest performers over the fourth quarter of 2009 were some of
the portfolio's smaller companies, with the six most material contributors to
performance all being listed on either AIM or the FTSE Fledgling Index. Carclo
(Chemicals; £90m market cap) and Dialight (Electronics; £80m market cap) both
benefited from an increased awareness of the value that LEDs will have both as
energy efficient and cost saving devices. Immunodiagnostics (Health; £190m
market cap), which was up almost 75% in the final three months, continued to
benefit from the value being placed by physicians on testing for Vitamin D and
consequently the company's diagnostic tests were in demand.
While top line growth will be hard to achieve in 2010 it can be found. There
will always be companies that succeed in under promising and over delivering on
earnings forecasts. As these businesses report 2009 results over the coming
months, we expect to see evidence that they have benefited from a combination
of improved competitive positions, weaker Sterling and cost-cutting. This
should leave them with every prospect of recording earnings upgrades and
continued good absolute returns for investors. In an environment that should
reward strong stock-picking, the Company continues to have £10m drawn down from
its facility with ING representing gearing of 10% at the end of 2009. This is
in marked contrast to a year ago when we were un-geared.
Material Events
The Board has announced that following many years of service, Mr Christopher
Jones will not be seeking re-election at the Company's 2010 AGM. Following Mr
Jones's retirement Mr Laurence Petar will be appointed the Senior Independent
Director. The Board has further announced its intention to appoint Miss Kathryn
Matthews as a non executive director with effect from 1 April 2010.
The Board is pleased to report that with effect from February 1st 2010 Charles
Montanaro resumed his role as the Portfolio Manager (at Montanaro Asset
Management) responsible for managing the Montanaro UK Smaller Companies
Investment Trust. Charles Montanaro was the Portfolio Manager from inception of
the Trust in 1995 until 2006. Charles is the Founder, CEO and CIO of Montanaro
Asset Management which today has a total staff of 23. The Board would like to
thank Dan Harlow for his involvement over the last 3 years and wish him well
for the future.
Top Ten Holdings as at 31 December 2009
Company Sector % of total portfolio
Hargreaves Services Support Services 2.7
Dignity General Retailers 2.5
Fisher (J) & Sons Industrial Transportation 2.5
eaga Support Services 2.4
Carclo Chemicals 2.4
Hill & Smith Industrial Engineering 2.4
Latchways Support Services 2.2
James Halstead Construction & Materials 2.2
Dechra Pharmaceuticals Pharmaceuticals & Biotechnology 2.2
Ricardo Support Services 2.1
23.6
Sector Breakdown
Sector % of total % of market
portfolio
Aerospace & Defense 3.3 2.3
Beverages 1.8 0.0
Chemicals 5.4 2.0
Construction & Materials 3.4 4.8
Electronic & Electrical 7.4 1.5
Equipment
Food & Drug Retailers 1.4 0.3
Food Producers 2.8 2.8
General Financial 6.0 5.5
General Retailers 6.4 6.6
Health Care Equipment & 5.9 3.4
Services
Household Goods 0.0 1.4
Industrial Engineering 4.0 3.4
Industrial Transportation 4.8 4.1
Leisure Goods 0.0 1.5
Life & Nonlife Insurance 0.0 4.4
Media 1.4 5.2
Mining 0.0 2.0
Oil & Gas Producers 2.8 1.6
Other 0.0 3.2
Pharmaceuticals & 3.0 4.1
Biotechnology
Real Estate 7.3 15.1
Software & Computer Services 7.5 6.8
Support Services 20.6 12.1
Technology Hardware & 0.0 1.5
Equipment
Travel & Leisure 4.8 4.4
100.0 100.0
This Interim Management Statement and up to date NAV and Share Price are
available at the Company's website www.montanarouksmaller.co.uk.
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.